Gynica Overview
Gynica is a biotech company driven to improve the lives of hundreds of millions of women worldwide suffering from Endometriosis by providing safe, effective, non-hormonal, intra-vaginal therapeutic solutions through its proprietary IntraVag© technology—a non-invasive, self-administered drug delivery platform. Endometriosis is a chronic and debilitating condition affecting at least 10%—more than 200 million—of women and girls of reproductive age worldwide, severely impacting their quality of life and overall well-being. Characterized by the abnormal growth of endometrial tissue outside the uterus, Endometriosis can cause a range of distressing symptoms, including intense pelvic pain, painful intercourse, menstrual irregularities, and infertility. Increasing awareness, improved diagnostic techniques, and the prevalence of the condition have given rise to the growing demand for safe and effective therapies in an underserved market—with a potential global annual market worth of $180 billion. Gynica is owned by Asana Bio Group, a holding company specializing in life sciences innovations.
Cumulative Funding Raised Over Time ($)
$2.0MJul 2019
$4.0MJun 2021
Latest News
growth-positive
Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis
Gynica, a clinical-stage womens health biotech startup, has announced the submission of a first-in-human Phase 1 trial for its novel Endometriosis treatment. The study, which will take place at Careggi University Hospital in Florence, Italy, will evaluate the safety, tolerability, and pharmacokinetics of the IntraVag intra-vaginal drug delivery platform and two proprietary drug candidates, S-301 and S-302. The company aims to develop a solution for Endometriosis, a disease affecting over 200 million women globally. Pending positive Phase 1 results, Gynica plans to advance into Phase 2 efficacy trials.
Investment
Israel's Gynica starts clinical trial for endometriosis
growth-positive
Meet the Israeli biotech start-up paving the way towards a next-generation treatment for endometriosis
The IVF Network, a fertility information and support provider, has debunked several common myths about infertility. The company clarified misconceptions such as the impact of abortions, COVID-19 vaccines, yeast infections, irregular periods, ovarian cysts, chlamydia, and endometriosis on fertility. It also highlighted that men can experience fertility issues and that infertility does not necessarily mean permanent childlessness. The IVF Network provides information, support, and advice to help people struggling to conceive make informed choices throughout their fertility journey.
Customers
growth-positive
Israeli Companies Seek to Transform Women's Health Care
Israeli FemTech company, OCON Healthcare, has developed a new form of intrauterine contraceptive device (IUD) called the IUB Ballerine. The device is smaller than traditional IUDs and is designed to fit more comfortably within the uterus, reducing the risk of irritation or damage. The IUB Ballerine is currently in use by over 120,000 women in Israel, Europe, and South Africa. OCON is also exploring ways to use the IUB as a platform for delivering drugs to the uterus to treat conditions such as abnormal menstrual bleeding, endometriosis, and uterine fibroids. The company is currently raising $25 million in investment to support its clinical and application process in the United States.
CustomersInvestmentExpand
growth-positive
HempStreet partners Israel's Gynica to develop phytopharma products - BioVoiceNews
HempStreet, Indias first research to retail venture in cannabis, has partnered with Gynica, an R&D company based out of Israel, to develop clinically-proven, robust phytopharmaceutical products to improve menstrual health and tackle other mass ailments. The partnership aims to strengthen their R&D capabilities. HempStreet has made significant progress in manufacturing natural relief products from cannabis, including its flagship menstrual pain product, Trailokya Vijaya Vati. Both HempStreet and Gynica have a strong focus on phytopharmaceutical products and will co-develop medical products for the Indian market specifically related to womens health.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $4M |
| Last funding | $2M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 1 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | gynica.com/ |
| Careers | Careers page |
Locations
Israel
Photos & Videos
No files yet
Gynica Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesMedical Devices IndustryMedical ProductsLife SciencesPharmaceuticalsBiotechnologyConsumersDemographics & FamilyWomenCore Technology
Materials & SubstancesRaw MaterialsBiologicalsHerbalsMoleculesTags (17)
biopharmaceuticalwomendrug-developmentcannabismedical-devicesdrug-discoverydrug-designgynecologywomen-healthmedical-technologiestherapeuticsbiotechnologypharmaceuticalsdrug-deliveryfemtechmedical-cannabispharma-companiesGeographic Markets
EuropeNorth AmericaAsiaSouth AmericaGynica Financials
$4M
Total funding
Undisclosed
Capital raised
$2M
Last funding
Seed
Funding stage
2
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$2.0MJul 2019
$4.0MJun 2021
Private Equity Funding
Seed
Jun 2021
$2M
Pre-Seed
Jul 2019
$2M
Undisclosed Investor(s)
Gynica Lifecycle
Cumulative Funding Raised Over Time
$2.0MJul 2019
$4.0MJun 2021
All Events
Seed
Jun 2021
$2M
Pre-Seed
Jul 2019
$2M
Undisclosed Investor(s)
Gynica News
12 articles
growth-positive
Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis
Gynica, a clinical-stage womens health biotech startup, has announced the submission of a first-in-human Phase 1 trial for its novel Endometriosis treatment. The study, which will take place at Careggi University Hospital in Florence, Italy, will evaluate the safety, tolerability, and pharmacokinetics of the IntraVag intra-vaginal drug delivery platform and two proprietary drug candidates, S-301 and S-302. The company aims to develop a solution for Endometriosis, a disease affecting over 200 million women globally. Pending positive Phase 1 results, Gynica plans to advance into Phase 2 efficacy trials.
Investment
Israel's Gynica starts clinical trial for endometriosis
growth-positive
Meet the Israeli biotech start-up paving the way towards a next-generation treatment for endometriosis
The IVF Network, a fertility information and support provider, has debunked several common myths about infertility. The company clarified misconceptions such as the impact of abortions, COVID-19 vaccines, yeast infections, irregular periods, ovarian cysts, chlamydia, and endometriosis on fertility. It also highlighted that men can experience fertility issues and that infertility does not necessarily mean permanent childlessness. The IVF Network provides information, support, and advice to help people struggling to conceive make informed choices throughout their fertility journey.
Customers
growth-positive
Israeli Companies Seek to Transform Women's Health Care
Israeli FemTech company, OCON Healthcare, has developed a new form of intrauterine contraceptive device (IUD) called the IUB Ballerine. The device is smaller than traditional IUDs and is designed to fit more comfortably within the uterus, reducing the risk of irritation or damage. The IUB Ballerine is currently in use by over 120,000 women in Israel, Europe, and South Africa. OCON is also exploring ways to use the IUB as a platform for delivering drugs to the uterus to treat conditions such as abnormal menstrual bleeding, endometriosis, and uterine fibroids. The company is currently raising $25 million in investment to support its clinical and application process in the United States.
CustomersInvestmentExpand
growth-positive
HempStreet partners Israel's Gynica to develop phytopharma products - BioVoiceNews
HempStreet, Indias first research to retail venture in cannabis, has partnered with Gynica, an R&D company based out of Israel, to develop clinically-proven, robust phytopharmaceutical products to improve menstrual health and tackle other mass ailments. The partnership aims to strengthen their R&D capabilities. HempStreet has made significant progress in manufacturing natural relief products from cannabis, including its flagship menstrual pain product, Trailokya Vijaya Vati. Both HempStreet and Gynica have a strong focus on phytopharmaceutical products and will co-develop medical products for the Indian market specifically related to womens health.
Partners
N/A
Femtech is coming of age in Israel - ISRAEL21c
The article discusses the concept of femtech, which refers to technology that advances the healthcare and wellbeing of women. It highlights the need for gender awareness in the development of technology and the challenges faced by the femtech industry in Israel, including awareness, investment, and diversity. The article features insights from four Israeli femtech leaders who express optimism about the growing interest in femtech and the potential for change in womens health. They emphasize the importance of educating investors and expanding the scope of femtech beyond traditional tech industries. The article concludes with a hopeful outlook for the future of femtech.
InvestmentDiversity
growth-positive
Comforting women: how Israeli start-up Gynica is helping women with cannabis-based products
Gynica, a company specializing in cannabis-based vaginal products, has completed preclinical studies and received approval from the Ministry of Health to conduct the worlds first clinical study on the impact of its proprietary cannabis-based vaginal products. The products, a vaginal suppository and lubricant, aim to provide relief for chronic menstrual pain and painful intercourse associated with endometriosis. Gynicas research team has been studying the health benefits of cannabis on the female reproductive system. The company is owned by The Asana Bio Group and has raised $5.55 million. The clinical trial is scheduled to take place in the first quarter of 2022.
Customers
growth-positive
Tikun Olam-Cannbit takes another step into the pharmaceutical arena
Tikun Olam Cannbit has acquired 20% of Gynica, a Femtech company that develops cannabinoid-based solutions for womens health. The acquisition agreement is part of Tikun Olam Cannbits strategy to become a cannabis-based pharmaceutical company. In exchange for the allocated shares, Tikun Olam Cannbit will provide Gynica with services for the development of vaginal suppositories, lubricating gel, and other products containing cannabinoids. They will also fund a joint clinical study led by Prof. Moshe Hod to develop a cannabis-based vaginal product for gynecological problems. Gynica specializes in scientific and technological medical cannabis innovation for women and is one of the first companies to conduct clinical research in this area. The partnership aims to improve the quality of life for women worldwide who have not received a safe and proper solution for their gynecological issues.
PartnersInvestment
growth-positive
כאבי מחזור? יתכן שקנאביס הוא הפיתרון - וואלה! כסף
Gynica, a medical cannabis company, has announced a strategic partnership with Altman Health to market CBD-based products for gynecological issues in Israel. Gynica has conducted pre-clinical research in the field of gynecology and is now conducting safety studies for its cannabis-based vaginal product. The new development offers local treatments for chronic menstrual pain and pain during sexual intercourse. The exclusive distribution of Gynicas CBD products in Israel will be handled by Altman. The Israeli CBD market potential in the nutrition, cosmetics, food, and beverage industries is estimated to be between $300-475 million within 5 years. Gynica is owned by Asana Bio Group and Lumir Lab, which is a strategic partner.
Partners
growth-positive
Gynica And Lumir Labs Partner Up To Find Marijuana-Based Endometriosis Treatment
Gynica is collaborating with Lumir Lab to find a cannabis-based treatment for endometriosis. The partnership aims to provide relief to the millions of women worldwide suffering from this condition. Gynica, led by Professor Moshe Hod, is focused on developing cannabis-based solutions for womens health. The company is dedicated to scientific research and improving the quality of life for patients. The collaboration with Lumir Lab, a research and development lab specializing in cannabinoids, will contribute to the discovery of innovative advancements in medical cannabis.
Partners
growth-positive
Strainprint™ Technologies, Lumir Lab and Gynica Announce Clinical Trial Partnership Establishing World's First and Largest Database of Medical Cannabis Effects on Women
Strainprint Technologies has announced a partnership with Lumir Lab and Gynica to conduct the worlds first international clinical study on the use of cannabis to treat endometriosis. The study aims to develop clinically-validated cannabinoid-based products for international distribution. Strainprints research platform will be used to provide support for in-clinic visits, including ethics approval, questionnaires, treatment tracking, and data visualization. The study will be conducted simultaneously in Israel and Canada, and up to 1,000 patients will be recruited in each country. The clinical study is expected to begin in Q2 of 2019.
Partners
growth-positive
Endometriosis latest target for medical cannabis research
Israeli startup Gynica will carry out research and development at the newly licensed Lumir Lab at the Hebrew University of Jerusalem. They will collaborate on a treatment for endometriosis, a condition affecting 180 million women worldwide. Gynica aims to understand the mechanisms of action and identify effective cannabinoids for eliminating endometriotic lesions. Asana Bio Group, a holding company specializing in medical cannabis ventures, made a $2.3 million investment in the Lumir Lab. The lab aims to set an international standard for clinically proven cannabis treatments.
PartnersInvestment
Gynica Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 18 classification IDs that could be used for matching.
Gynica Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Hilla Gorokhovsky |
| Registrar ID | 516107174 |
| Crunchbase | gynica |
| Phone | 0528888188 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-02-16T00:00:00.000Z |
| Created | 2019-06-24T00:00:00.000Z |
| Claimed | Yes |